- Global Pharma News & Resources

Pharmerging Market to Hit US$1.40 Billion by 2024, Says TMR

ALBANY, New York, Feb. 22, 2019 /PRNewswire/ --

As per the market research report by TMR, in 2015, the global pharmerging market stood at US$552.8 mn and is predicted to reach a value of US$1.40 bn by 2024. The market is further anticipated to register a promising 11.30% CAGR from 2016 to 2024. Based on economic growth levels, pharmerging market is divided into tier-I, tier-II, and tier-III. These are distributed among countries such as Tier-I include China while Tier-II includes Brazil, India, and Russia. Tier-III includes Indonesia, Thailand, Mexico, Turkey, Egypt, Vietnam, and South Africa.

Get PDF Brochure for Research Insights at

In the last few years, Asia Pacific held a huge share of the pharmerging market and is estimated to remain in the same position over the next few years. The high rate of urbanization and the tremendous rise in investments for medical research are predicted to ensure the development of this region in the next few years. Also, the rising patent expiration and the increasing contribution from China are further projected to enhance the growth in the near future.

Healthcare Sector Boosts the Growth Opportunities Worldwide

Different components are driving the global pharmerging market expecting to depend vigorously on considerable gives by different governments and interests in an offer to convey its endeavors of R&D for the upcoming level.  While considering consumption rates, the healthcare sector is most likely to profit players operating in the global pharmerging market. Players are being tossed into importance through enormous interest displayed by numerous individuals of the real governing bodies and governments.

Request a Sample of Report at

Increase in the private and public healthcare insurance, and coordinated effort in pharmerging are boosting the global pharmerging market. Apart from these, mergers and acquisitions among MNCs are increasing the mindfulness among individuals in regards to pharmerging. Along with, expanding government activity for pharmerging across the world are the prime development drivers of global pharmerging market. Likewise, increment in accepting of pharmerging in developing economies, like, China, and others, will make new open doors for global pharmerging market. Another driving factor for the global pharmerging market is rise healthcare expenditure. The global healthcare spending is expected to increase in the forthcoming years.

Request For Discount On This Report -

Increasing Competition among Pharmaceutical Organizations Is Hindering the Market

There is n-number of large and small-scale retailers who has highly fragmented the pharmerging markets. Difficulties such as cost pressure, administrative requirements, and competitiveness from global and local pharmaceutical organizations. A large portion of the global pharmaceutical organizations faces these type of competitions. Dominant pharmaceutical tycoons are concentrating on technical advancements, product expansions, and inorganic strategies through mergers and acquisitions. These are expected to intensify growth in the global pharmerging market in the forthcoming years.

Request For Custom Research -

The global pharmerging market is highly fragmented and competitive, Transparency Market Research based on a recently published report. This is because of the presence of a large number of entrants who are competing to stay on top. In the close term, the global pharmerging market is probably going to observe an escalated challenge with the passage of various emerging new players. In order to be ahead in the global pharmerging market, some of the key players are seen focusing on collaborations and strategic mergers and acquisitions. They are also investing considerable amount of money into R&D of better products. Deploying such approaches, some of the firms that have come to hold a dominant position in it are Sun Pharmaceutical Industries Ltd., Huadong Medicine Co. Ltd., LUPIN, GlaxoSmithKline Plc., AstraZeneca and Tata Consultancy Services Ltd, among others.

Browse Press Release -

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled, "Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024."

Popular Research Reports by TMR:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Research Blog:

Editor Details

Last Updated: 22-Feb-2019